Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tice.2025.102738 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum "pde4b
4
"pde4b abrogation
4
abrogation extenuates
4
extenuates angiotensin
4
angiotensin ii-induced
4
ii-induced endothelial
4
endothelial dysfunction
4
dysfunction hypertension
4
hypertension up-regulation
4
up-regulation ampk/sirt1/nrf2/are
4
Similar Publications
Corrigendum to "PDE4B abrogation extenuates angiotensin II-induced endothelial dysfunction related to hypertension through up-regulation of AMPK/Sirt1/Nrf2/ARE signaling" [Tissue Cell 91 (2024) 102637].
Tissue Cell
January 2025
Cardiovascular Department, Yueqing Second People's Hospital, Hongqiao Town, Yueqing City, Zhejiang Province 325608, China.
Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis.
Front Pharmacol
May 2023
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
[This corrects the article DOI: 10.3389/fphar.2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!